Вы находитесь на странице: 1из 36

80

DAFTAR PUSTAKA

1. Creager M, Libby P. Peripheral Arterial Disease In: Mann DL, Zipes DP,
Libby P, Bonow RO, editors. Braunwald’s Heart Disease : A Textbook of
Cardiovascular Medicine. 10th ed. Philadelphia: Elsevier Saunders; 2015.
1312 p.

2. Antono D, Hamonangani R. Penyakit Arteri Perifer. In: Setiati S, editor.


Buku Ajar Ilmu Penyakit Dalam. 1st ed. Jakarta: InternaPublishing; 2014.
p. 1516–26.

3. Rhee SY, Kim YS. Peripheral Arterial Disease in Patients with Type 2
Diabetes Mellitus. 2015;283–90.

4. Coffman JD, Eberhardt RT. Peripheral Arterial Disease, Diagnosis and


Treatment. New York: Springer Seienee&Business Media; 2003.1-34p.

5. Rooke TW, Hirsch a. T, Misra S, Sidawy a. N, Beckman J a., Findeiss LK,


et al. 2011 ACCF/AHA Focused Update of the Guideline for the
Management of Patients With Peripheral Artery Disease. Circulation.
Elsevier Inc.; 2011;58(19):2020–45.

6. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott


MM, et al. Comparison of global estimates of prevalence and risk factors
for peripheral artery disease in 2000 and 2010: a systematic review and
analysis. Lancet. Elsevier Ltd; 2013;382(9901):1329–40.

7. Selvin E. Prevalence of and Risk Factors for Peripheral Arterial Disease in


the United States: Results From the National Health and Nutrition
Examination Survey, 1999-2000. Circulation. 2004;110(6):738–43.

8. Fowkes FGR, Low LP, Tuta S, Kozak J. Ankle-brachial index and extent of
atherothrombosis in 8891 patients with or at risk of vascular disease:
Results of the international AGATHA study. Eur Heart J.
2006;27(15):1861–7.

9. Rhee SY, H G, ZM L, SW-K C, S W, P P. Multi-country study on the


prevalence and clinical features of peripheral arterial disease in Asian type
2 diabetes patients at high risk of atherosclerosis. Diabetes Res Clin Pract.
2007;76(1):82–92.

10. American Diabetes Association. Epidemiology and Impact of Peripheral


Arterial Disease in People with Diabetes. Diabetes Care.
2003;26(12):3333–41.
81

11. American Heart Association. What is peripheral vascular disease? In


American Heart Association; 2012.

12. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL,
et al. ACC/AHA 2005 Practice Guidelines for the Management of Patients
With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and
Abdominal Aortic). Circulation. 2006;113(11):e463–5.

13. Norgren L, Hiatt WR, Dormandy J a., Nehler MR, Harris K a., Fowkes
FGR, et al. Inter-Society Consensus for the management of peripheral
arterial disease (TASC II). Int Angiol. 2007;26(2):82–157.

14. F Brian Boudi M. Coronary Artery Atherosclerosis Treatment &


Management. Medscape. 2016; [cited 2016 Jun 17]

15. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J
Am Coll Cardiol. 2006;47(5):921–9.

16. The Japan Diabetes Society. Evidence-based Practice Guideline for the
Treatment for Diabetes in Japan 2013. Diabet Med. 2013;1–3.

17. Ilmiah Populer [Internet]. [cited 2016 Jan 26]. Available from:
http://www.pdpersi.co.id/content/popular_science.php?psid=30

18. Dinas Kesehatan Jateng. Daftar Tabel Profil Kesehatan Provinsi Jawa
Tengah. Semarang: Dinkes Jateng; 2008. 38 p.

19. Huh JH, Choi E, Lim JS, Lee MY, Chung CH, Shin JY. Serum cystatin C
levels are associated with asymptomatic peripheral arterial disease in type 2
diabetes mellitus patients without overt nephropathy. Diabetes Res Clin
Pract. Elsevier Ireland Ltd; 2015;108(2):258–64.

20. Rahman A. Faktor – Faktor Risiko Mayor Aterosklerosis pada Berbagai


Penyakit Aterosklerosis di RSUP Dr. Kariadi Semarang. Diponegoro
University; 2012.

21. Tomeleri CM, Ronque ER, Silva DR, Cardoso Junior CG, Fernandes R a,
Teixeira DC, et al. Prevalence of dyslipidemia in adolescents: comparison
between definitions. Rev Port Cardiol. Sociedade Portuguesa de
Cardiologia; 2015;34(2):103–9.

22. Bittner V. Perspectives on dyslipidemia and coronary heart disease in


women: an update. Curr Opin Cardiol. 2006;21(6):602–7.

23. Fakhrzadeh H, Tabatabaei-malazy O. Dyslipidemia and Cardiovascular


Disease. Endocrinol Metab Res Cent Tehran Univ Med Sci. 2008;
82

24. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar


(RISKESDAS) 2007. Lap Nas 2007. 2008;1–384.

25. Rinandyta SA. Perbedaan Kadar LDL pada Penderita Diabetes Melitus
Tipe 2 dengan Hipertensi dan Tanpa Hipertensi di RSUD Dr. Moewardi.
Universitas Muhammadiyah Surakarta; 2012.

26. Ilminovia F. Hubungan antara Status Diabetes Melitus dengan Status


Penyakit Arteri Perifer (PAP) pada Pasien Hipertensi In Abstract Book
ESC 26th. European student congress; 2015.

27. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J,
editors. Harrison’s Principles of Internal Medicine. 18th ed. New York: Mc
Graw Hill; 2012. 2066 p.

28. Agrawal K, Eberhardt RT. Contemporary Medical Management of


Peripheral Arterial Disease. Cardiol Clin. Elsevier Inc; 2015;33(1):111–37.

29. Runge MS, Greganti MA. Netter’s Internal Medicine. 2nd ed. Philadelphia:
Saunders Elsevier; 2009. 213 p.

30. McDermott, M M, McGrae. Lower Extremity Manifestations of Peripheral


Artery Disease. Am Hear Assoc J. 2015;115:1540–50.

31. Lozano FS, González-Porras JR, March JR, Lobos JM, Carrasco E, Ros E.
Diabetes mellitus and intermittent claudication: a cross-sectional study of
920 claudicants. Diabetol Metab Syndr. 2014;6:21.

32. Hallett Jr JW. Peripheral Arterial Disease. Merck Manuals. 2008;169–73.

33. Bordeaux LM, Reich LM, Hirsch AT. The Epidemiology and Natural.
Springer J. 2003;(Ic):21–35.

34. Baker. Smoking and Peripheral Arterial Disease ( PAD ). ASH Research
Report Smoking and Peripheral Arterial Disease. 2014;

35. Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clement D, Collet


J-P, et al. ESC Guidelines on the diagnosis and treatment of peripheral
artery diseases: Document covering atherosclerotic disease of extracranial
carotid and vertebral, mesenteric, renal, upper and lower extremity arteries
* The Task Force on the Diagnosis and Treat. Eur Heart J.
2011;32(22):2851–906.

36. Olin JW, Sealove B a. Peripheral artery disease: current insight into the
disease and its diagnosis and management. Mayo Clin Proc.
2010;85(7):678–92.
83

37. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG. Peripheral


arterial disease detection, awarness and treatment in primary care. JAMA.
2001;286(11):1317–24.

38. Age AT. Peripheral Arterial Disease in the Legs. In: CdcGov. p. 4–5.

39. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL.
ACC/AHA 2005 practice guidelines for the Management of Patients with
Peripheral Arterial Disease (lower extremity, renal, mesenteric, and
abdominal aortic): a collaborative report from the American Association for
Vascular Surgery/Society for Vascular Sur. Circulation. 2006;113(11):463–
654.

40. Suyono S. Diabetes Melitus. In: Setiati S, editor. Buku Ajar Ilmu Penyakit
Dalam. 1st ed. Jakarta: InternaPublishing; 2014. p. 2315–418.

41. American Diabetes Association. Classification and Diagnosis of Diabetes.


Diabetes Care. 2015;38(Supplement_1):S8–16.

42. Hirsch a T, Hiatt WR. PAD awareness, risk, and treatment: new resources
for survival--the USA PARTNERS program. Vasc Med. 2001;6(3
Suppl):9–12.

43. Joshua A, Beckman, MD M, Mark A. Creager M, Peter Libby M. Diabetes


and Atherosclerosis Epidemiologi, Pathophysiology, and Management.
JAMA. 2002;(287):2570–81.

44. Coggins M, Lindner J, Rattigan S, Jahn L, Fasy E, Kaul S, et al. Muscle


Perfusion by Capillary Recruitment. 2001;50

45. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function.
European Heart Journal. 2012;33(7):829–37.

46. Hua L, Hongliang L, Yige B, Xiangxun Z, Yerong Y. Free Fatty Acids


Induce Endothelial Dysfunction and Activate Protein Kinase C and Nuclear
Factor-κB Pathway in Rat Aorta. Int J Cardiol. 152(2):218–24.

47. Erwinanto, Santoso A, Putranto JNE, Tedjasukmana P, Suryawan R, Rifqi


S, et al. Pedoman tatalaksana dislipidemia. 1st ed. Perhimpunan Dokter
Spesialis Kardiovaskular Indonesia; 2013.1-7p.

48. PERKENI. Konsensus Pengelolaan Dislipidemia di Indonesia. Jakarta:


Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Kedokteran UI; 2012.15-
21p.
84

49. Fodor G. Primary prevention of CVD: Treating dyslipidemia. Am Fam


Physician. 2011;83(10):1207–8.

50. Adam JM. Dislipidemia. In: Setiati S, editor. Buku Ajar Ilmu Penyakit
Dalam. 1st ed. Jakarta: InternaPublishing; 2014. p. 2549–68.

51. Forouzandeh F, Salazar G, Patrushev N, Xiong S, Hilenski L, Fei B, et al.


Metformin beyond diabetes: Pleiotropic benefits of metformin in
attenuation of atherosclerosis. J Am Heart Assoc. 2014;3(6):1–12.

52. Jamkhande PG, Chandak PG, Dhawale SC, Barde SR, Tidke PS, Sakhare
RS. Therapeutic approaches to drug targets in atherosclerosis. Saudi Pharm
J SPJ Off Publ Saudi Pharm Soc. King Saud University; 2014;22(3):179–
90.

53. Elizabeth Klodas M. High Blood Pressure and Atherosclerosis. WebMD.


2016; [cited 2016 Jun 17]

54. Aboyans V, Criqui MH, Abraham P, Allison M a., Creager M a., Diehm C,
et al. Measurement and Interpretation of the Ankle-Brachial Index: A
Scientific Statement From the American Heart Association. Circulation.
2012;126(24):2890–909.

55. Mahameed A Al. Peripheral Arterial Disease. Cleve Clin J Med. 2009;

56. Bonham P, Cappuccio M, Hulsey T, Michel Y, Kelechi T, Jenkins C. Are


Ankle and Toe Brachial Indices (ABI-TBI) Obtained by a Pocket Doppler
Interchangeable With Those Obtained by Standard Laboratory Equipment?
J Wound, Ostomy Cont Nurs. 2007;34(1):35–44.

57. Carmo G a L, Mandil a, Nascimento BR, Arantes BD, Bittencourt JC,


Falqueto EB, et al. Can we measure the ankle-brachial index using only a
stethoscope? A pilot study. Fam Pract. 2009;26(1):22–6.

58. WOCN Wound Committee. Ankle Brachial Index. J Wound, Ostomy Cont
Nurs. 2012;39(April):S21–9.

59. Inada A, Weir GC, Bonner-Weir S. Induced ICER I?? down-regulates


cyclin a expression and cell proliferation in insulin-producing ?? cells.
Biochem Biophys Res Commun. 2005;329(3):925–9.

60. Yogiantoro M. Hipertensi Esensial. Buku Ajar Ilmu Penyakit Dalam Jilid
1. IV. Jakarta: FKUI; 2006. 610-14 p.

61. F Brian Boudi M. Treatment of Low HDL levels and High Triglyceride
levels in Patients With Diabetes. Medscape. 2016;[cited 2016 Jun 17]
85

62. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial
disease in the United States: Results from the National Health and Nutrition
Examination Survey, 1999-2000. Circulation. 2004;110(6):738–43.

63. Pepine CJ, Handberg EM. The vascular biology of hypertension and
atherosclerosis and intervention with calcium antagonists and angiotensin-
converting enzyme inhibitors. Clin Cardiol. 2001;24(11 Suppl):V1–5.
86

Lampiran 1. Informed Consent (Persetujuan Pasien)

JUDUL PENELITIAN : Hubungan antara Dislipidemia dengan Derajat


Keparahan Penyakit Arteri Perifer (PAP) pada
Pasien Diabetes Melitus Tipe 2 Terkontrol Sedang.
INSTANSI PELAKSANA : Bagian Ilmu Penyakit Dalam FK Undip -
Mahasiswa Program Studi Strata-1 Kedokteran
Umum Fakultas Kedokteran Universitas
Diponegoro

PERSETUJUAN SETELAH PENJELASAN

(INFORMED CONSENT)

Yth Bapak/Ibu …………………………………..

Nama saya Eka Aryani, saya mahasiswa Program Studi S1 Ilmu


Pendidikan Dokter Fakultas Kedokteran UNDIP. Saya melakukan penelitian
dengan judul “Hubungan antara Dislipidemia dengan Derajat Keparahan Penyakit
Arteri Perifer (PAP) pada Pasien Diabetes Melitus Tipe 2 Terkontrol Sedang”.
Tujuan dari penelitian ini adalah untuk mengetahui hubungan antara dislipidemia
dengan derajat keparahan penyakit arteri perifer (PAP) pada pasien DM tipe 2
terkontrol sedang. Dislipidemia adalah kelainan metabolisme lipid (lemak darah)
dimana terjadi peningkatan maupun penurunan komponen lipid seperti kolesterol
total, kolesterol LDL (Low Density Lipoprotein), TG (trigliserida), serta
menurunnya kolesterol HDL (High Density Lipoprotein) dalam darah. Penyakit
arteri perifer adalah gangguan suplai darah ke ekstremitas atas atau bawah
(tungkai atau lengan) karena obstruksi atau sumbatan sehingga timbul gejala
seperti rasa nyeri pada ekstremitas tersebut(klaudikasio intermiten). Bapak/Ibu
87

terpilih sebagai peserta penelitian ini. Apabila Bapak/Ibu setuju untuk menjadi
peserta penelitian maka ada beberapa hal yang akan Bapak/Ibu alami, yaitu:
- Pengambilan informasi nama, umur, jenis kelamin, status merokok, status
hipertensi dan keluhan yang dirasakan melalui wawancara
- Diukur tekanan darah pada kedua kaki dan kedua lengan pada saat istirahat
- Dan bila diperlukan, akan diukur tekanan darah pada kaki setelah berolah
raga naik-turun bangku selama 4-5 menit atau berjalan selama 6 menit atau
dorsofleksi plantarfleksi selama 6 menit.
Keuntungan bagi Bapak/Ibu yang bersangkutan ikut dalam penelitian ini
adalah mendapat fasilitas pendeteksian Penyakit Arteri Perifer (PAP) serta
mengetahui derajat PAP yang diderita apabila terdeteksi. Dengan dilakukanya
pendeteksian ini, kita dapat mengetahui apakah terdapat sumbatan pembuluh
darah pada lengan atau kaki Bapak/Ibu. Bapak/Ibu juga akan diberi pemahaman
mengenai PAP. Saya menjamin bahwa penelitian ini tidak akan menimbulkan
efek yang merugikan pada Bapak/Ibu. Dalam penelitian ini tidak ada intervensi
dalam bentuk apapun terhadap Bapak/ Ibu. Setiap data pemeriksaan dan penelitian
dijamin kerahasiaannya dengan tidak mencantumkan identitas subyek. Sebagai
peserta penelitian keikutsertaan ini bersifat sukarela dan tidak dikenakan biaya
penelitian.

Penanggung jawab penelitian:


Eka Aryani
085642702444
Sudah mendengar dan memahami penjelasan penelitian, dengan ini saya
menyatakan
SETUJU / TIDAK SETUJU
untuk ikut sebagai subyek/sampel penelitian ini.

Tegal, …………………….2016

Saksi
Nama Terang : Nama Terang :
Alamat : Alamat :
88

Lampiran 2

DAFTAR TILIK PENELUSURAN REKAM MEDIK


No Keterangan
Nama
Jenis Kelamin
Umur
Alamat
No HP
Kontrol teratur/tidak
Status merokok ya/ tidak
DM
Status glikemik (HbA1c):
Kadar gula darah terakhir
GDS:
GDP:
Lamanya DM:
Obat yang diminum:
Dislipidemia ya/ tidak
TC:
LDL:
HDL:
TG:
Lamanya dislipidemia:
Obat yang diminum:
Hipertensi
Tekanan darah terakhir:
Obat yang diminum:
89

Lampiran 3

LEMBAR PENGUMPULAN DATA


ANKLE-BRACHIAL INDEX (ABI)
Tanggal Pemeriksaan:
Nama Pasien: Umur:
Catatan: Jenis Kelamin:
Apakah ada aktivitas berat yang baru
saja dilakukan/ konsumsi kafein/
alkohol terakhir

ABI saat istirahat


Kanan Pengukuran Rata- Kiri Pengukuran Rata-
I II rata I II rata
Brachialis Brachialis
Tibialis Tibialis
Posterior Posterior
Dorsalis Dorsalis
Pedis Pedis

rata − rata tertinggi tekanan sistolik kaki kanan DP atau TP


ABI kanan =
rata − rata tertinggi tekanan sistolik lengan kanan atau kiri

rata − rata tertinggi tekanan sistolik kaki kiri DP atau TP


ABI kiri =
rata − rata tertinggi tekanan sistolik lengan (kanan atau kiri)

Nilai ABI saat istirahat =


90

ABI setelah exercise


(Diakukan apabila nilai ABI saat istirahat normal namun terdapat gejala
klaudikasio)
Lamanya exercise =
Nilai tekanan sistolik kaki setelah exercise =
Nilai ABI setelah exercise =

Kelengkapan Data
Status Merokok :
Lamanya DM :
Lamanya Dislipidemia
Minum obat hipertensi teratur atau tidak :
Minum obat diabetes teratur atau tidak :
Minum obat dislipidemia teratur atau tidak :
91

Lampiran 4. Izin Penelitian


92
93

Lampiran 5. Dokumentasi Penelitian


94
95

Lampiran 6. Biodata Mahasiswa


Identitas

Nama Lengkap : Eka Aryani


Jenis Kelamin : Perempuan
Program Studi : Pendidikan Dokter
NIM : 22010112110093
Tempat, tanggal lahir : Tegal, 14 Februari 1995
E-mail : eka.aryani1402@gmail.com
Nomor telepon/HP : 085642702444

Riwayat Pendidikan Formal


SD SMP SMA S1
Nama Institusi SDN SMPN 18 SMAN 1 Kota Pendidikan
Margadana 3 Kota Tegal Tegal Dokter
Kota Tegal Fakultas
Kedokteran
UNDIP
Tahun masuk- 2000-2006 2006-2009 2009-2012 2012
lulus

Organisasi yang Pernah Diikuti:


Lembaga Tahun
Divisi Pengembangan Mahasiswa 2013-2014
Kelompok Studi Mahasiswa FK
UNDIP
Bidang Riset HIMA KU UNDIP 2012-2014
Kelompok Ilmiah Remaja SMAN 1 2010-2012
Kota Tegal

Pengalaman Mengikuti Lomba Karya Ilmiah


Potensi Teng-teng Natto sebagai Alternatif Terapi Aterosklerosis, LKTI-GT Mini
Scientific Fair 2014, Peserta Terbaik.
96

Lampiran 7. Hasil SPSS

Frequencies
Frequency Table
Status Dislipidemia
Frequency Percent Valid Percent Cumulative
Percent
ya 21 70,0 70,0 70,0
Valid tidak 9 30,0 30,0 100,0
Total 30 100,0 100,0

Jenis kelamin
Frequency Percent Valid Percent Cumulative
Percent
Laki-laki 17 56,7 56,7 56,7
Valid Perempuan 13 43,3 43,3 100,0
Total 30 100,0 100,0

Usia
Valid 30
N
Missing 0
Mean 59,17
Median 58,50
Std. Deviation 7,250
Minimum 46
Maximum 71
Usia
Frequency Percent Valid Percent Cumulative
Percent
46 2 6,7 6,7 6,7
50 2 6,7 6,7 13,3
51 1 3,3 3,3 16,7
52 1 3,3 3,3 20,0
53 2 6,7 6,7 26,7
Valid 54 2 6,7 6,7 33,3
55 2 6,7 6,7 40,0
57 1 3,3 3,3 43,3
58 2 6,7 6,7 50,0
59 1 3,3 3,3 53,3
62 1 3,3 3,3 56,7
97

64 3 10,0 10,0 66,7


65 2 6,7 6,7 73,3
66 2 6,7 6,7 80,0
67 3 10,0 10,0 90,0
68 2 6,7 6,7 96,7
71 1 3,3 3,3 100,0
Total 30 100,0 100,0

Status merokok
Frequency Percent Valid Percent Cumulative
Percent
Ya 6 20,0 20,0 20,0
pasif 5 16,7 16,7 36,7
Valid mantan 3 10,0 10,0 46,7
tidak 16 53,3 53,3 100,0
Total 30 100,0 100,0

Hipertensi
Frequency Percent Valid Percent Cumulative
Percent
Ya 13 43,3 43,3 43,3
Valid Tidak 17 56,7 56,7 100,0
Total 30 100,0 100,0

Penyakit atherosclerosis lain


Frequency Percent Valid Percent Cumulative
Percent
Ya 7 23,3 23,3 23,3
Valid Tidak 23 76,7 76,7 100,0
Total 30 100,0 100,0

Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Status Dislipidemia * Status 30 100,0% 0 0,0% 30 100,0%
PAP
98

Status Dislipidemia * Status PAP Crosstabulation


Status PAP Total
Ya Tidak
Count 12 9 21
Expected Count 8,4 12,6 21,0
ya
% within Status PAP 100,0% 50,0% 70,0%
% of Total 40,0% 30,0% 70,0%
Status Dislipidemia
Count 0 9 9
Expected Count 3,6 5,4 9,0
tidak
% within Status PAP 0,0% 50,0% 30,0%
% of Total 0,0% 30,0% 30,0%
Count 12 18 30
Expected Count 12,0 18,0 30,0
Total
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%

Chi-Square Tests
Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)
a
Pearson Chi-Square 8,571 1 ,003
b 6,356 1 ,012
Continuity Correction

Likelihood Ratio 11,699 1 ,001

Fisher's Exact Test ,004 ,003

Linear-by-Linear Association 8,286 1 ,004

N of Valid Cases 30

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 3,60.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
For cohort Status PAP = ,429 ,262 ,702
Tidak
N of Valid Cases 30
99

T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
Ya 12 212,00 45,798 13,221
Kolesterol total
Tidak 9 164,33 34,077 11,359

Independent Samples Test


Levene's t-test for Equality of Means
Test for
Equality of
Variances
F Sig. t df Sig. (2- Mean Std. 95% Confidence
tailed) Differenc Error Interval of the
e Differenc Difference
e Lower Upper
Equal variances 1,62 ,218 2,61 19 ,017 47,667 18,199 9,577 85,757
Kolester assumed 2 9
ol total Equal variances 2,73 18,999 ,013 47,667 17,430 11,184 84,149
not assumed 5

T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
Ya 12 136,83 31,007 8,951
LDL
Tidak 9 104,44 30,566 10,189

Independent Samples Test


Levene's Test for t-test for Equality of Means
Equality of
Variances
F Sig. t df Sig. (2- Mean Std. 95% Confidence
tailed) Differenc Error Interval of the
e Differenc Difference
e Lower Upper
Equal variances ,042 ,840 2,383 19 ,028 32,389 13,591 3,942 60,836
assumed
LDL
Equal variances 2,388 17,52 ,028 32,389 13,562 3,841 60,937
not assumed 3
100

T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
Ya 12 25,58 9,549 2,756
HDL
Tidak 9 33,67 5,074 1,691

Independent Samples Test


Levene's Test for t-test for Equality of Means
Equality of Variances
F Sig. t df Sig. (2- Mean Std. Error 95% Confidence
tailed) Differenc Differenc Interval of the
e e Difference
Lower Upper
Equal variances 4,985 ,038 - 19 ,033 -8,083 3,517 -15,445 -,721
assumed 2,298
HDL
Equal variances - 17,44 ,023 -8,083 3,234 -14,893 -1,273
not assumed 2,499 3

NPar Tests

Mann-Whitney Test
Ranks
Status PAP N Mean Rank Sum of Ranks
Ya 12 13,42 161,00
Trigliserida Tidak 9 7,78 70,00
Total 21
a
Test Statistics
Trigliserida

Mann-Whitney U 25,000
Wilcoxon W 70,000
Z -2,061
Asymp. Sig. (2-tailed) ,039
b
Exact Sig. [2*(1-tailed Sig.)] ,041
a. Grouping Variable: Status PAP
b. Not corrected for ties.
101

Crosstabs
Case Processing Summary

Cases

Valid Missing Total


N Percent N Percent N Percent
jumlah dislipidemia * Status PAP 21 100,0% 0 0,0% 21 100,0%

jumlah dislipidemia * Status PAP Crosstabulation


Status PAP Total
Ya Tidak
Count 0 6 6
Expected Count 3,4 2,6 6,0
1 komponen
% within Status PAP 0,0% 66,7% 28,6%
% of Total 0,0% 28,6% 28,6%
Count 9 3 12
Expected Count 6,9 5,1 12,0
2 komponen
% within Status PAP 75,0% 33,3% 57,1%
% of Total 42,9% 14,3% 57,1%
jumlah dislipidemia
Count 2 0 2
Expected Count 1,1 ,9 2,0
3 komponen
% within Status PAP 16,7% 0,0% 9,5%
% of Total 9,5% 0,0% 9,5%
Count 1 0 1
Expected Count ,6 ,4 1,0
4 komponen
% within Status PAP 8,3% 0,0% 4,8%
% of Total 4,8% 0,0% 4,8%
Count 12 9 21
Expected Count 12,0 9,0 21,0
Total
% within Status PAP 100,0% 100,0% 100,0%
% of Total 57,1% 42,9% 100,0%
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
a
Pearson Chi-Square 11,813 3 ,008
Likelihood Ratio 15,186 3 ,002
Linear-by-Linear Association 8,710 1 ,003
N of Valid Cases 21

a. 6 cells (75,0%) have expected count less than 5. The minimum expected count is
,43.
102

Frequencies
jenis komponen
Frequency Percent Valid Percent Cumulative
Percent
HDL 4 19,0 19,0 19,0
TG 2 9,5 9,5 28,6
TC HDL 1 4,8 4,8 33,3
HDL TG 10 47,6 47,6 81,0
Valid
LDL HDL 1 4,8 4,8 85,7
TC LDL HDL 2 9,5 9,5 95,2
TC LDL HDL TG 1 4,8 4,8 100,0
Total 21 100,0 100,0

NPar Tests
Descriptive Statistics

N Mean Std. Minimum Maximum Percentiles


Deviation
25th 50th 75th
(Median)
jenis 21 3,57 1,720 1 7 2,00 4,00 4,00
komponen
Status PAP 21 1,43 ,507 1 2 1,00 1,00 2,00
103

Mann-Whitney Test
Ranks
Status PAP N Mean Rank Sum of Ranks
Ya 12 14,38 172,50
jenis komponen Tidak 9 6,50 58,50
Total 21

a
Test Statistics
jenis komponen

Mann-Whitney U 13,500
Wilcoxon W 58,500
Z -3,059
Asymp. Sig. (2-tailed) ,002
b
Exact Sig. [2*(1-tailed Sig.)] ,002
a. Grouping Variable: Status PAP
b. Not corrected for ties.

Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Jenis kelamin * Status PAP 30 100,0% 0 0,0% 30 100,0%

Jenis kelamin * Status PAP Crosstabulation


Status PAP Total
Ya Tidak
Count 6 11 17
Expected Count 6,8 10,2 17,0
Laki-laki
% within Status PAP 50,0% 61,1% 56,7%
% of Total 20,0% 36,7% 56,7%
Jenis kelamin
Count 6 7 13
Expected Count 5,2 7,8 13,0
Perempuan
% within Status PAP 50,0% 38,9% 43,3%
% of Total 20,0% 23,3% 43,3%
Count 12 18 30
Expected Count 12,0 18,0 30,0
Total
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%
104

Chi-Square Tests
Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)
a
Pearson Chi-Square ,362 1 ,547
b ,051 1 ,821
Continuity Correction
Likelihood Ratio ,361 1 ,548

Fisher's Exact Test ,711 ,410

Linear-by-Linear Association ,350 1 ,554

N of Valid Cases 30

a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 5,20.
b. Computed only for a 2x2 table

Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Jenis kelamin ,636 ,145 2,784
(Laki-laki / Perempuan)
For cohort Status PAP = Ya ,765 ,320 1,828
For cohort Status PAP = 1,202 ,651 2,220
Tidak
N of Valid Cases 30

T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
Ya 12 61,08 6,302 1,819
Usia
Tidak 18 57,89 7,722 1,820

Independent Samples Test


Levene's Test for t-test for Equality of Means
Equality of
Variances
F Sig. t df Sig. (2- Mean Std. 95% Confidence
tailed) Differenc Error Interval of the
e Differenc Difference
e Lower Upper
Equal variances 1,788 ,192 1,191 28 ,244 3,194 2,683 -2,300 8,689
assumed
Usia
Equal variances 1,241 26,72 ,225 3,194 2,574 -2,089 8,477
not assumed 0
105

Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Status merokok * Status 30 100,0% 0 0,0% 30 100,0%
PAP

Status merokok * Status PAP Crosstabulation


Status PAP Total
Ya Tidak
Count 4 2 6
Expected Count 2,4 3,6 6,0
Ya
% within Status PAP 33,3% 11,1% 20,0%
% of Total 13,3% 6,7% 20,0%
Count 3 2 5
Expected Count 2,0 3,0 5,0
pasif
% within Status PAP 25,0% 11,1% 16,7%
% of Total 10,0% 6,7% 16,7%
Status merokok
Count 1 2 3
Expected Count 1,2 1,8 3,0
mantan
% within Status PAP 8,3% 11,1% 10,0%
% of Total 3,3% 6,7% 10,0%
Count 4 12 16
Expected Count 6,4 9,6 16,0
tidak
% within Status PAP 33,3% 66,7% 53,3%
% of Total 13,3% 40,0% 53,3%
Count 12 18 30
Expected Count 12,0 18,0 30,0
Total
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%

Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
a
Pearson Chi-Square 4,167 3 ,244
Likelihood Ratio 4,199 3 ,241
Linear-by-Linear Association 3,902 1 ,048
N of Valid Cases 30
106

a. 6 cells (75,0%) have expected count less than 5. The minimum


expected count is 1,20.

Risk Estimate
Value
a
Odds Ratio for Status
merokok (Ya / pasif)

a. Risk Estimate statistics cannot be


computed. They are only computed for a
2*2 table without empty cells.

Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Hipertensi * Status PAP 30 100,0% 0 0,0% 30 100,0%

Hipertensi * Status PAP Crosstabulation


Status PAP Total
Ya Tidak
Count 9 4 13
Expected Count 5,2 7,8 13,0
Ya
% within Status PAP 75,0% 22,2% 43,3%
% of Total 30,0% 13,3% 43,3%
Hipertensi
Count 3 14 17
Expected Count 6,8 10,2 17,0
Tidak
% within Status PAP 25,0% 77,8% 56,7%
% of Total 10,0% 46,7% 56,7%
Count 12 18 30
Expected Count 12,0 18,0 30,0
Total
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%
107

Chi-Square Tests
Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)
a
Pearson Chi-Square 8,167 1 ,004
b 6,160 1 ,013
Continuity Correction
Likelihood Ratio 8,488 1 ,004

Fisher's Exact Test ,008 ,006

Linear-by-Linear Association 7,895 1 ,005

N of Valid Cases 30

a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 5,20.
b. Computed only for a 2x2 table

Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Hipertensi 10,500 1,889 58,359
(Ya / Tidak)
For cohort Status PAP = Ya 3,923 1,320 11,656
For cohort Status PAP = ,374 ,161 ,869
Tidak
N of Valid Cases 30

Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Penyakit atherosclerosis lain 30 100,0% 0 0,0% 30 100,0%
* Status PAP

Penyakit atherosclerosis lain * Status PAP Crosstabulation


Status PAP Total
Ya Tidak
Count 4 3 7
Expected Count 2,8 4,2 7,0
Ya
% within Status PAP 33,3% 16,7% 23,3%
Penyakit atherosclerosis lain
% of Total 13,3% 10,0% 23,3%
Count 8 15 23
Tidak
Expected Count 9,2 13,8 23,0
108

% within Status PAP 66,7% 83,3% 76,7%


% of Total 26,7% 50,0% 76,7%
Count 12 18 30
Expected Count 12,0 18,0 30,0
Total
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%

Chi-Square Tests
Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)
a
Pearson Chi-Square 1,118 1 ,290
b ,380 1 ,537
Continuity Correction

Likelihood Ratio 1,100 1 ,294

Fisher's Exact Test ,392 ,266

Linear-by-Linear Association 1,081 1 ,299

N of Valid Cases 30

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 2,80.
b. Computed only for a 2x2 table

Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Penyakit 2,500 ,445 14,037
atherosclerosis lain (Ya /
Tidak)
For cohort Status PAP = Ya 1,643 ,701 3,849
For cohort Status PAP = ,657 ,266 1,626
Tidak
N of Valid Cases 30

Crosstabs
Minum obat * Status PAP Crosstabulation
Status PAP Total
Ya Tidak
Count 6 16 22
Expected Count 8,8 13,2 22,0
Teratur
Minum obat % within Status PAP 50,0% 88,9% 73,3%
% of Total 20,0% 53,3% 73,3%
Tidak teratur Count 6 2 8
109

Expected Count 3,2 4,8 8,0


% within Status PAP 50,0% 11,1% 26,7%
% of Total 20,0% 6,7% 26,7%
Count 12 18 30
Expected Count 12,0 18,0 30,0
Total
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%

Chi-Square Tests
Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)
a
Pearson Chi-Square 5,568 1 ,018
b 3,757 1 ,053
Continuity Correction
Likelihood Ratio 5,601 1 ,018

Fisher's Exact Test ,034 ,027

Linear-by-Linear Association 5,383 1 ,020

N of Valid Cases 30

a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 3,20.
b. Computed only for a 2x2 table

Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Minum obat ,125 ,020 ,799
(Teratur / Tidak teratur)
For cohort Status PAP = Ya ,364 ,165 ,802
For cohort Status PAP = 2,909 ,853 9,925
Tidak
N of Valid Cases 30

Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Obat dislipidemia * Status 30 100,0% 0 0,0% 30 100,0%
PAP
110

Obat dislipidemia * Status PAP Crosstabulation


Status PAP Total
Ya Tidak
Count 5 3 8
Expected Count 3,2 4,8 8,0
ya
% within Status PAP 41,7% 16,7% 26,7%
% of Total 16,7% 10,0% 26,7%
Count 7 8 15
Expected Count 6,0 9,0 15,0
Obat dislipidemia tidak
% within Status PAP 58,3% 44,4% 50,0%
% of Total 23,3% 26,7% 50,0%
Count 0 7 7
Expected Count 2,8 4,2 7,0
tidak minum obat
% within Status PAP 0,0% 38,9% 23,3%
% of Total 0,0% 23,3% 23,3%
Count 12 18 30
Expected Count 12,0 18,0 30,0
Total
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%

Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
a
Pearson Chi-Square 6,632 2 ,036
Likelihood Ratio 9,068 2 ,011
Linear-by-Linear Association 5,695 1 ,017
N of Valid Cases 30

a. 4 cells (66,7%) have expected count less than 5. The minimum


expected count is 2,80.

Risk Estimate
Value
a
Odds Ratio for Obat
dislipidemia (ya / tidak)

a. Risk Estimate statistics cannot be


computed. They are only computed for a
2*2 table without empty cells.
111

Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
obat hipertensi * Status PAP 30 100,0% 0 0,0% 30 100,0%

obat hipertensi * Status PAP Crosstabulation


Status PAP Total
Ya Tidak
Count 5 2 7
Expected Count 2,8 4,2 7,0
teratur
% within Status PAP 41,7% 11,1% 23,3%
% of Total 16,7% 6,7% 23,3%
Count 4 2 6
Expected Count 2,4 3,6 6,0
obat hipertensi tidak teratur
% within Status PAP 33,3% 11,1% 20,0%
% of Total 13,3% 6,7% 20,0%
Count 3 14 17
Expected Count 6,8 10,2 17,0
tidak minum obat
% within Status PAP 25,0% 77,8% 56,7%
% of Total 10,0% 46,7% 56,7%
Count 12 18 30
Expected Count 12,0 18,0 30,0
Total
% within Status PAP 100,0% 100,0% 100,0%
% of Total 40,0% 60,0% 100,0%

Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
a
Pearson Chi-Square 8,198 2 ,017
Likelihood Ratio 8,523 2 ,014
Linear-by-Linear Association 7,016 1 ,008
N of Valid Cases 30

a. 4 cells (66,7%) have expected count less than 5. The minimum


expected count is 2,40.
112

Risk Estimate
Value
a
Odds Ratio for obat
hipertensi (teratur / tidak
teratur)

a. Risk Estimate statistics cannot be


computed. They are only computed for a
2*2 table without empty cells.

Logistic Regression
Case Processing Summary
a
Unweighted Cases N Percent
Included in Analysis 30 100,0
Selected Cases Missing Cases 0 ,0
Total 30 100,0
Unselected Cases 0 ,0
Total 30 100,0
a. If weight is in effect, see classification table for the total number of cases.

Dependent Variable Encoding


Original Value Internal Value
Ya 0
Tidak 1
Categorical Variables Codings
Frequency Parameter coding
(1)
Teratur 22 1,000
Minum obat
Tidak teratur 8 ,000
Ya 13 1,000
Hipertensi
Tidak 17 ,000

Block 0: Beginning Block


a,b
Classification Table
Observed Predicted
Status PAP Percentage
Ya Tidak Correct
Ya 0 12 ,0
Status PAP
Step 0 Tidak 0 18 100,0
Overall Percentage 60,0

a. Constant is included in the model.


113

b. The cut value is ,500


Variables in the Equation
B S.E. Wald df Sig. Exp(B)

Step 0 Constant ,405 ,373 1,184 1 ,277 1,500

Variables not in the Equation


Score df Sig.

Hipertensi(1) 8,167 1 ,004


Variables
Step 0 obat_dm(1) 5,568 1 ,018
Overall Statistics 10,027 2 ,007

Block 1: Method = Backward Stepwise (Likelihood Ratio)


Omnibus Tests of Model Coefficients
Chi-square df Sig.

Step 10,792 2 ,005


Step 1 Block 10,792 2 ,005
Model 10,792 2 ,005
Step -2,303 1 ,129
a
Step 2 Block 8,488 1 ,004
Model 8,488 1 ,004
a. A negative Chi-squares value indicates that the Chi-squares
value has decreased from the previous step.

Model Summary
Step -2 Log likelihood Cox & Snell R Nagelkerke R
Square Square
a
1 29,589 ,302 ,408
a
2 31,892 ,246 ,333
a. Estimation terminated at iteration number 4 because parameter
estimates changed by less than ,001.

Hosmer and Lemeshow Test


Step Chi-square df Sig.
1 ,070 2 ,966
2 ,000 0 .
114

Contingency Table for Hosmer and Lemeshow Test


Status PAP = Ya Status PAP = Tidak Total
Observed Expected Observed Expected
1 5 5,124 1 ,876 6
2 4 3,876 3 3,124 7
Step 1
3 1 ,876 1 1,124 2
4 2 2,124 13 12,876 15
1 9 9,000 4 4,000 13
Step 2
2 3 3,000 14 14,000 17

a
Classification Table
Observed Predicted
Status PAP Percentage
Ya Tidak Correct
Ya 9 3 75,0
Status PAP
Step 1 Tidak 4 14 77,8
Overall Percentage 76,7
Ya 9 3 75,0
Status PAP
Step 2 Tidak 4 14 77,8
Overall Percentage 76,7

a. The cut value is ,500

Variables in the Equation

B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B)

Lower Upper
Hipertensi(1) -2,017 ,919 4,820 1 ,028 ,133 ,022 ,805
a
Step 1 obat_dm(1) 1,552 1,048 2,190 1 ,139 4,719 ,604 36,836
Constant ,250 1,055 ,056 1 ,813 1,284

Hipertensi(1) -2,351 ,875 7,219 1 ,007 ,095 ,017 ,529


a
Step 2
Constant 1,540 ,636 5,863 1 ,015 4,667

a. Variable(s) entered on step 1: Hipertensi, obat_dm.


115

Model if Term Removed


Variable Model Log Change in -2 Log df Sig. of the
Likelihood Likelihood Change
Hipertensi -17,390 5,190 1 ,023
Step 1
obat_dm -15,946 2,303 1 ,129
Step 2 Hipertensi -20,190 8,488 1 ,004
Variables not in the Equation
Score df Sig.

a
Variables obat_dm(1) 2,360 1 ,124
Step 2
Overall Statistics 2,360 1 ,124
a. Variable(s) removed on step 2: obat_dm.